Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 4/20 | 0.38 |
| ▸ | CDK1 | P06493 | 4/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.38 |
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.37 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.37 |
| ▸ | AHR | P35869 | 3/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366153 | 0.81 | GRIA1 (0.42) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL3524460 | 0.78 | AHR (0.41) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL5366860 | 0.78 | GRIA1 (0.41) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL18210028 | 0.78 | SRC (0.41) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL687996 | 0.78 | DRD2 (0.46) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL12335925 | 0.78 | HTR1D (0.39) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL18289479 | 0.77 | AHR (0.50) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL2472436 | 0.75 | CCNB2 (0.36) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL9835372 | 0.74 | P2RX7 (0.40) | GRIA1CACNG8AHRPDK2DRD2 | |
| SCHEMBL5368729 | 0.74 | DRD2 (0.40) | CCNB2CDK1CCNB1GSK3BCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168648-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. | 2024-03-21 | — | — | US | disclosed |
| EP-4320105-A1 | OPIOID RECEPTOR MODULATORS | Epiodyne, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117425644-A | Opioid receptor modulators | 埃皮欧黛公司 | 2024-01-19 | — | — | CN | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-10 | — | — | US | disclosed |
| WO-2022216750-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20010056094-A1 | Anticarcinogenic agents | TANG PENG CHO (US) | 2001-12-27 | — | — | US | disclosed |
| US-6316429-B1 | ENZYME INHIBITORS MODULATE THE ACTIVITY OF PROTEIN KINASES AND THEREFORE ARE EXPECTED TO BE USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER. | SUGEN, INC. | 2001-11-13 | — | — | US | disclosed |
| US-6313158-B1 | THERAPY AND PROPHYLAXIS OF CANCER | SUGEN, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1066257-A2 | HETEROCYLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | Sugen, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999048868-A9 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN INC (US) | 2000-04-20 | — | — | WO | disclosed |
| US-6051593-A | USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN TYROSINE KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0984930-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | Sugen, Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1998050356-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | CCNB2 4720/4885CDK1 3614/4885CCNB1 4691/4885 |
| US-12168648-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | CCNB2 4720/4885CDK1 3614/4885CCNB1 4691/4885 |
| US-20010056094-A1 | Anticarcinogenic agents | GSTK1, CDC42BPG, GLS | CCNB2 1246/4885CDK1 361/4885CCNB1 897/4885 |
| US-11634396-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | CCNB2 4720/4885CDK1 3614/4885CCNB1 4691/4885 |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | CCNB2 4720/4885CDK1 3614/4885CCNB1 4691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.